Biosimilars, 10 Years & Counting
Since the Biologics Price Competition and Innovation Act of 2010 (BPCIA), 26 biosimilars have been approved, providing patients with lower-cost, life-changing medicines, which treat cancer, rheumatoid arthritis, Crohn’s and more, but not all of them are accessible to patients. Biosimilars are just as safe and effective as brand biologics. As Americans look for ways to lower drug costs, increasing access and use of biosimilars will provide millions of U.S. patients with the cost-saving benefits from this growing category of drugs.
Help reflect on these last ten years and discuss how to make the next ten years even better by sharing the Instagram card and including #b10similars on your social media posts to engage physicians, patients and policymakers in the journey and potential of biosimilars.